How were Impax Laboratories' earnings last quarter?

Impax Laboratories, Inc. (NASDAQ:IPXL) issued its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.03. The specialty pharmaceutical company earned $206.40 million during the quarter, compared to analysts' expectations of $208.38 million. Impax Laboratories's quarterly revenue was down 9.4% compared to the same quarter last year. During the same period last year, the firm posted $0.37 EPS.

What other stocks do shareholders of Impax Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Impax Laboratories investors own include Chembio Diagnostics (CEMI) , Prospect Capital (PSEC) , Calumet Specialty Products Partners (CLMT) , Two Harbors Investment (TWO) , NovoCure (NVCR) , BlackRock Capital Investment (BKCC) , Summit Midstream Partners (SMLP) , Washington Prime Group (WPG) , Viper Energy (VNOM) and Roper Technologies (ROP) .

NASDAQ:IPXL

Impax Laboratories (IPXL) Stock Price, News & Analysis

→ The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad)

Free IPXL Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $17.40
▼
$18.95
50-Day Range: $18.30
▼
$18.30
52-Week Range: $13.05
▼
$25.70

Volume: 3.04 million shs
Average Volume: 945,265 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Impax Laboratories alerts:

Ad TradeSmith

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

About Impax Laboratories Stock (NASDAQ:IPXL)

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Ad TradeSmith

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

IPXL Stock News Headlines

September 10, 2023 | investing.com

Impax Sustainable Allocation Fund Investor Class (PAXWX)

May 23, 2023 | seekingalpha.com

KBLB Kraig Biocraft Laboratories, Inc.

April 19, 2024 | TradeSmith (Ad)

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

May 11, 2023 | wsj.com

Ferozsons Laboratories Ltd.

April 5, 2023 | wsj.com

Impax Ellevate Global Women's Leadership Fund;Individual Investor

April 3, 2023 | thestreet.com

Impax Stock Hits New 52-Week High (IPXL)

March 28, 2023 | financialpost.com

Impax CEO Says Funds Have Run Out of 'Investible' Green Assets

September 29, 2022 | investing.com

Morepen Laboratories Ltd (MORL)

April 19, 2024 | TradeSmith (Ad)

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

September 9, 2022 | fool.com

Abbott Laboratories (NYSE: ABT)

July 27, 2022 | thestreet.com

Clearside Biomedical Inc. News

See More Headlines

Receive IPXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impax Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2017
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:IPXL
CUSIP: 45256B10
CIK: 1003642
Web: www.impaxlabs.com
Phone: (908) 947-3120
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Chintu Patel
Co-Chief Executive Officer & Director
Chirag K. Patel
President & Co-Chief Executive Officer & Director
Andrew S. Boyer
Executive Vice President-Commercial Operations
Anastasios G. Konidaris
Chief Financial Officer & Senior Vice President
Nikita Shah
Chief Human Resources Officer & Senior VP

Key Competitors

View All Competitors

IPXL Stock Analysis - Frequently Asked Questions

How were Impax Laboratories' earnings last quarter?: Impax Laboratories, Inc. (NASDAQ:IPXL) issued its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.03. The specialty pharmaceutical company earned $206.40 million during the quarter, compared to analysts' expectations of $208.38 million. Impax Laboratories's quarterly revenue was down 9.4% compared to the same quarter last year. During the same period last year, the firm posted $0.37 EPS.
What other stocks do shareholders of Impax Laboratories own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Impax Laboratories investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), NovoCure (NVCR), BlackRock Capital Investment (BKCC), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Viper Energy (VNOM) and Roper Technologies (ROP).

This page (NASDAQ:IPXL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Impax Laboratories (IPXL) Stock Price, News & Analysis

About Impax Laboratories Stock (NASDAQ:IPXL)

IPXL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

IPXL Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info